Personalis Inc Stock News

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026. Recent Strategic and Operational Highlights Launched NeXT Personal® Real-Time Variant Tracker™: Commercially launched optional Real-Time Variant Tracker supplemental results in th...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Sp...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the commercial launch of optional Real-Time Variant Tracker supplemental results in the NeXT Personal molecular residual disease (MRD) test report. These results identify clinically relevant resistance and therapeutically targetable variants over time, during NeXT Persona...

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus ​AI said ‌on Monday ​it ​would acquire ⁠Personalis ​for about $1.5 ​billion to bringing ​its ​cancer test ‌to ⁠the AI-enabled precision ​medicine ​firm's ⁠oncology portfolio.